FCF Healthcare & Life Sciences Venture Capital Monitor
-
USA

The FCF Healthcare & Life Sciences Venture Capital Monitor – USA is a monthly published overview of venture capital trends in the US Healthcare & Life Sciences sector.

FCF Healthcare & Life Sciences Venture Capital Monitor - USA

As of the end of May 2025 we identified the following current VC trends in the United States: 

  • Total Healthcare & Life Sciences funding reached EUR 15,796m (-9% vs. 2024) 
  • Biotech/Pharma received 40% of the total investment volume (EUR 6,357m) with oncology being the leading indication (27%) 
  • In May Neuralink secured thehighest transaction volume withEUR 576m, followed byPathos with EUR 327m and Lumicell withEUR 176m 
  • Illumina (United States) is the most active investor (by deal volume in 2025), followed by Regeneron Pharmaceuticals (United States) and Bain Capital Life Sciences (United States) 

NEWS